



#12  
gnd

1644

Dkt. 65019-DA-PCT-US/JPW/AJM

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Marc Feldmann and Ravinder N. Maini  
Serial No. : 09/754,004 Examiner: P. Gambel  
Filed : January 3, 2001 Group Art Unit: 1644  
For : TNF $\alpha$  ANTAGONISTS AND METHOTREXATE IN THE TREATMENT OF TNF-MEDIATED DISEASE

1185 Avenue of the Americas  
New York, New York 10036  
September 13, 2002

Assistant Commissioner for Patents  
Washington, D.C. 20231

**RECEIVED**

SEP 20 2002

Sir:

**TECH CENTER 1600/2900**

COMMUNICATION IN RESPONSE TO  
AUGUST 13, 2002 RESTRICTION REQUIREMENT

This Communication is submitted in response to the Restriction Requirement issued August 13, 2002 in connection with the above-identified application. A response to the August 13, 2002 Office Action is due September 13, 2002. Accordingly, this response is being timely filed.

In the Office Action, the Examiner required, under 35 U.S.C. §121, election of a single disclosed species from the previously elected category of autoimmune disease.

In response, applicants hereby elect with traverse the species of psoriatic arthritis for prosecution, in the event no generic claim is held allowable. Psoriatic arthritis is recited in the specification at, *inter alia*, page 7, line 11.


If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned


Applicants: Marc Feldmann, et al.  
Serial No.: 09/754,004  
Filed: January 3, 2001  
Page 2

attorneys invite the Examiner to telephone them at the number provided below.

No fee is deemed necessary in connection with the filing of this Communication. However, if any fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,

  
John P. White  
Registration No. 28,678  
Alan J. Morrison  
Registration No. 37,399  
Attorneys for Applicants  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
Tel. No. (212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents  
Washington, D.C. 20231.  
  
Alan J. Morrison Date  
Reg. No. 37,399